Bharat Parenterals (NSE:BPLPHARMA) Cyclically Adjusted PS Ratio: (As of Aug. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:BPLPHARMA Bharat Parenterals Ltd NSE:BPLPHARMA
55 GF Score
Price ₹1,294.70
GF Value ₹1,232.25
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Bharat Parenterals Cyclically Adjusted PS Ratio?

Note: If the price history is too short, we do not calculate current Cyclically Adjusted PS Ratio for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Bharat Parenterals  (NSE:BPLPHARMA) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Bharat Parenterals Cyclically Adjusted PS Ratio Related Terms


Bharat Parenterals Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Bharat Parenterals's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bharat Parenterals Cyclically Adjusted PS Ratio Chart

Bharat Parenterals Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 2.34 1.95

Bharat Parenterals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.66 2.78 2.66 1.95 2.93

NSE:BPLPHARMA vs : Cyclically Adjusted PS Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Bharat Parenterals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bharat Parenterals Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Bharat Parenterals's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Bharat Parenterals's Cyclically Adjusted PS Ratio falls into.


NSE:BPLPHARMA
55GF Score
Bharat Parenterals Ltd NSE:BPLPHARMA
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bharat Parenterals Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Bharat Parenterals's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Bharat Parenterals's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=136.008/333.9520*333.9520
=136.008

Current CPI (Jun. 2026) = 333.9520.

Bharat Parenterals Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 46.669 241.428 64.554
201612 47.188 241.432 65.271
201703 57.851 243.801 79.243
201706 47.319 244.955 64.511
201709 64.631 246.819 87.447
201712 56.276 246.524 76.234
201803 70.086 249.554 93.789
201806 64.921 251.989 86.037
201809 88.304 252.439 116.818
201812 156.193 251.233 207.620
201903 73.134 254.202 96.078
201906 86.579 256.143 112.879
201909 86.815 256.759 112.915
201912 129.428 256.974 168.199
202003 95.560 258.115 123.637
202006 95.745 257.797 124.029
202009 103.998 260.280 133.435
202012 86.475 260.474 110.869
202103 70.402 264.877 88.762
202106 106.178 271.696 130.507
202109 105.447 274.310 128.374
202112 66.586 278.802 79.757
202203 90.596 287.504 105.232
202206 45.264 296.311 51.014
202209 141.916 296.808 159.676
202212 102.305 296.797 115.112
202303 87.507 301.836 96.818
202306 121.140 305.109 132.592
202309 101.943 307.789 110.608
202312 94.952 306.746 103.374
202403 109.109 312.332 116.662
202406 141.800 314.175 150.726
202409 109.795 315.301 116.290
202412 132.934 315.605 140.662
202503 150.868 319.799 157.545
202506 168.310 322.561 174.254
202509 124.966 324.800 128.487
202512 94.585 324.054 97.474
202603 144.550 330.213 146.187
202606 136.008 333.952 136.008

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Bharat Parenterals (NSE:BPLPHARMA) Overvalued in 2026?

Based on GuruFocus' analysis, Bharat Parenterals stock appears to be overvalued. The current stock price of ₹1,294.70 is trading 5.1% above its estimated GF Value™ of ₹1,232.25. GuruFocus considers Bharat Parenterals to be Fairly Valued.

Key valuation signals for NSE:BPLPHARMA:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: ₹1,232.25 vs. price of ₹1,294.70 (5.1% above fair value)
  • GF Score™: 55/100 with 5 warning signs

No single metric tells the full story. See the NSE:BPLPHARMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Bharat Parenterals Business Description

Comparable Companies
Other Exchanges 541096:India
Address Survey No.144-A, Jarod Samlaya Road, Village Haripura, Tehsil Savli, Vadodara, GJ, IND, 391520
Bharat Parenterals Ltd is a pharmaceutical company. It provides various products such as Capsules, Dry Syrups, Sachets, Oral Liquids, Injections, Semisolids, and others. Geographically, the group has a business presence in India and Outside India.
55GF Score

Get the complete analysis for NSE:BPLPHARMA

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,294.70
Price
₹1,232.25
GF Value